Cyclosporine A, a calcineurin inhibitor, has improved allograft survival in solid organ transplantation and has been increasingly applied in the management of autoimmune diseases. While marked progress has been made in patient and allograft survival rates, clinical use of CsA is often limited by its nephrotoxic effect, which can be presented as two distinct and well characterized forms: acute and chronic nephrotoxicity. The acute form is characterized by renal vasoconstriction, induced by an imbalance of vasoactive substances release, which leads to renal dysfunction. This form is reversible. The chronic toxicity, in contrast, is characterized by the vasoconstriction plus the development of structural damage that includes arteriolopathy and tubulointerstitial fibrosis that are often not reversible. The exact mechanisms of these deleterious effects are not fully understood, but major advances have occurred over the last few years. Here we review the current literature regarding the pathogenesis and strategies that have been used to ameliorate renal injury in chronic CsA nephrotoxicity.
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The introduction of cyclosporine A (CsA) into clinical transplantation two decades ago as an immunosuppressive agent to prevent allograft rejection lead to a significant improvement in both allograft half-life and patient survival (16). Immunosuppressive action of CsA is mediated by formation of a complex with cyclophilin, which in turn inhibits the activity of protein phosphatase 2B, calcineurin. Hence, CsA is also known as calciuneurin inhibitor. One consequence of calcineurin inactivation is the prevention of nuclear factor of activated T cells (NFAT-1) dephoshporylation and transfer to the nucleus. NFAT-1 is an important regulatory protein that up regulates the transcription and production of IL-2 and other cytokines that promote the growing and proliferation of T and B cells (56) . Two forms of CsA renal toxicity have been described: acute and chronic nephropathy. The acute form is characterized by renal vasoconstriction induced by an imbalance of vasoactive substance release which in turn produces a fall in renal function. This form of toxicity is presented as a reversible acute renal failure when CsA administration is diminished or withdrawn. In contrast, the chronic form of nephrotoxicity is characterized not only by renal vasoconstriction, but also by the development of structural damage including arteriolopathy and tubulo-interstitial fibrosis that are Page 3 of 32 irreversible and may lead to end stage renal disease (3; 29; 39) . This review is focused in studies using CsA, because most of the studies addressing the issue of nephrotoxicity by calcineurin inhibitors have been performed with this agent.
Mechanisms of CsA nephrotoxicity
Experimental models of CsA nephrotoxicity in rats have been helpful in the study of pathophysiological mechanisms involved in the development and maintenance of renal toxicity. Acute and chronic forms of CsA nephrotoxicity can be reproduced in rats.
The acute form is induced by administration of repeated doses of CsA by subcutaneous injection, from a range that varies from 15 to 50 mg/kg/day for 7 to 28 days. The chronic model requires that, in addition to CsA administration at similar doses for at least 15 days, the animals should be fed with low sodium diet (3; 19; 20; 27; 44; 55) , suggesting that for some reason activation of the renin angiotensin aldosterone system is required in rats to induce the CsA-related structural injury in the kidney.
Using the models described above, studies in which glomerular hemodynamics were analyzed by renal micropuncture techniques reveled that CsA administration is associated with afferent and efferent arteriolar vasoconstriction, predominating preglomerular vasoconstriction that results in a significant reduction of renal plasma flow (QA). A reduction of utrafiltration coefficient (Kf) has also been observed. The decrease in these two hemodynamic variables lead to a significant reduction of single nephron glomerular filtration rate and thus, renal dysfunction (7; 10; 11). Precise mechanism by which CsA induced renal vasoconstriction has not been clearly established. Results from several studies indicate that vascular dysfunction induced by CsA results from an Several factors have been implicated in the development of structural injury during chronic CsA nephrotoxicity. These are 1) activation of renin angiotensin aldosterone system in which angiotensin II, through the activation of AT1 receptors, not only participates in renal vasoconstriction, but also promotes fibrotic processes and the release of aldosterone (47; 58), 2) renal hypoxia that results from renal vasoconstriction induced by CsA leads to the formation of reactive oxygen species (11; 34)that cause cellular injury and promote cellular death by apoptosis (77; 78) , and 3) up-regulation of transforming growth factor (TGF-), that promotes renal fibrosis by increasing the production and decreasing the degradation of extracellular matrix proteins (20; 33; 58; 72).
Strategies to prevent or reduce chronic CsA nephrotoxicity
Because the use of CsA as an immunosuppressive agent to prevent allograft rejection has been limited by its toxic effects, several groups have studied potential strategies to prevent or reduce CsA nephrotoxicity. Acute toxicity is reversible, while chronic toxicity in which histological changes occur, is non-reversible and increases the risk of end stage renal disease. Thus, most of the studies have been performed using chronic model of toxicity in which rats are fed a low salt diet during the period of CsA Vasoconstrictor effect of CsA on renal vasculature has been shown to be involved in the pathogenesis of CsA toxicity. As we mentioned before, a group of strategies have been based toward blocking the effect of vasoconstrictor factors such as losartan as an antagonist of angiotensin II receptor 1 (64), BQ123 for its properties as endothelin receptors blocker (26) , and L-arginine as substrate for NO synthase producing NO to counteract renal vasoconstriction (5; 57). Although losartan was able to reduce tubulointerstitial fibrosis by ~50%, no improvement was observed in renal function. In fact, a further decrease in creatinine clearance was observed in rats treated with CsA and losartan, probably secondary to losartan-induced fall in efferent resistance. Antagonism of both receptors, endothelin A and B with BQ123 improved renal function by ~30%, but was unable to reduce renal structural injury. These observations agree with Kon et al. (28) which suggested that endothelin is at least partially responsible for afferent vasoconstriction. However, the slight increase in renal function was not associated with improvement of renal structural damage. In contrast, chronic L-arginine administration increased renal function by ~70% and reduced tubulo-interstitial injury by ~50%. This protective effect was associated with a reduction of vascular endothelial growth factor (VEGF) and suggests that the reestablishment of renal blood flow due to increased availability of NO was associated with lesser structural injury.
A second group of studies included two different treatments of anti-inflammatory drugs, such as pentosan polysulfate (55) and mycophenolate mofetil (61) . Schwadler et al. (55) observed that pentosan polysulfate was able to reduced arteriolar lesions and tubulo-interstitial fibrosis by ~45%, but this treatment did not prevent CsA-induced Page 6 of 32 decrease of creatinine clearance. Shihab et al. (61) reported that mycophenolate mofetil is capable of improving neither renal function nor structural injury produced by CsA.
Thus, anti-inflammatory drugs are not able to improve renal function in CsA treated rats and had limited benefit on preventing renal structural injury.
A third group of studies included drugs with anti-fibrotic properties such as TGFantibody, statins, pirfenidone, and hepatocyte growth factor. Because central role of TGF-in the development of renal injury induced by calcineurin inhibitors, the effect TGF-neutralizing monoclonal antibody administration was studied. As table 1 shows, this strategy reduced renal structural injury by ~40%. Although renal function was not determined, serum creatinine levels were significantly lower in mice that received TGFantibody than in untreated mice, suggesting that neutralization of TGF-, in addition to expected reduction in renal fibrosis, also improved renal function by mechanism that remains to be determined. Previous studies in cultured mesangial cells (23) and in rats with diabetic nephropathy (22) have shown that TGF up-regulation induced glomerular injury through activation of calcineurin, which in turn induced greater NFAT translocation to the nucleus, resulting in mesangial proliferation and extracellular matrix (ECM) accumulation. In the diabetic rats these effects were reduced by CsA administration in glomerular, but not in tubulointerstitial area (22) and reduced tubulo-interstitial fibrosis by ~55%. Mechanisms implicated were suppression of osteopontin, TGF-and intrarenal C-reactive protein expression together with higher eNOS expression (70) . However, the beneficial effect of pravastatin in very high doses (20 mg/kg) was not observed in rats that received lower doses (5 mg/kg).
Another antifibrotic agent that has been tested in chronic CsA nephrotoxicity is pirfenidone. The mechanism of action of this compound is unclear but available data suggest that pirfenidone inhibits TGF-actions. Shihab et al. (59; 60) showed that simultaneous administration of pirfenidone to CsA treated and salt-depleted rats did significantly reduced tubulo-interstitial fibrosis by ~50%. This antifibrotic effect was accompanied by a reduction of TGF-protein expression and matrix deposition, as well as by reduction of cell death by apoptosis and expression of regulatory genes of apoptosis. Finally, hepatocyte growth factor has also been reported to protect from renal injury as an antifibrotic factor. Misui et al (38) showed a slight reduction of renal fibrosis by hepatocyte growth factor gene transfer in chronic CsA nephrotoxicity (~25%), an effect that was accompanied by a reduction of TGF-mRNA levels and apoptosis. Thus, antifibrotic approaches such as TGF-antibody, pravastatin, pirfenidone, and hepatocyte growth factor can be of help in reducing renal fibrosis.
Supplementation of magnesium is another strategy that has been shown to be helpful in correcting hypomagnesaemia in Sprague-Dawley rats with chronic CsA nephrotoxicity (37). Asai et al. (6) observed that magnesium supplementation prevented renal dysfunction induced by CsA. In this study, vehicle treated rats had a creatinine clearance of 2.1 ± 04 ml/min. Renal function was decreased by CsA to 0.8 ± 0.1 ml/min Page 8 of 32 and this effect was partially reversed by magnesium supplementation to a value of 1.7 ± 0.1 ml/min. Simultaneously, renal structural damage was also prevented. Authors observed that rats treated with CsA in which magnesium was supplemented exhibited a reduction of osteopontin, monocyte chemoattractant protein-1, TGF-, and endothelin mRNA levels, associated with a decrease of monocyte/macrophage influx into renal tissue. Because the beneficial effects of magnesium supplementation were not observed when the renin angiotensin system was inhibited with angiotensin converting enzyme inhibitor benazepril, the authors concluded that the protective effect of magnesium supplementation was independent of angiotensin II. Mechanism by which magnesium supplementation was able to prevent CsA-toxicity was not elucidated. Interestingly, however, the protective effect of magnesium supplementation was not observed in two Although in both studies hypomagnesemia was successfully corrected by exposing rats to drinking water containing 2% MgCl 2 , the reduction in glomerular filtration rate was not prevented by this maneuver. In addition, we have observed that hypomagnesemia does not occur in Wistar rats with acute or chronic CsA nephrotoxicity. In our experience, plasma magnesium levels in vehicle and CsA-treated animals under low sodium diet for 21 days were 2.1 ± 0.1 and 2.6 ± 0.1, respectively. Thus, in Wistar rats CsA nephrotoxicity is developed in the absence of hypomagnesemia, suggesting that at least in this model, CsA-toxicity is not related to magnesium deficiency. Another strategy reported is a dietary supplementation with fish oil. Homan et al. (68) observed that recipients of primary cadaveric kidney transplant treated with CsA that ingested fish oil daily during the first postoperative year had higher glomerular filtration rate and renal plasma flow than those not ingesting fish oil. However, a more recent randomized, double blind, placebo controlled in tansplant patients taking CsA showed no beneficial effect of fish oil on GFR and RPF, as well as in renal histopathology. In addition, two studies, tested the effect of randomized pentoxifilline administration, a hemorrheologic agent, to cardiac transplant patients treated with CsA. Renal dysfunction induced by CsA was similar between pentoxifilline and placebo group (21; 74). A similar effect has been observed in CsA treated renal transplant recipients receiving also CGS 12970 a thromboxane synthase inhibitor (63) . Thus, of all potential preventing treatments tested in humans to reduce CsA nephrotoxicity, the only one that showed beneficial effects was the use of renal vasodilators like calcium channel blocker. Table 1 Figure 1D , once chronic CsA nephrotoxicity was established after 18 days of treatment and confirmed through renal function and structural analysis, one group of rats received simultaneously CsA and spironolactone during 18 days more and was compared with a group that received only CsA for a similar period of time. It was observed that MR blockade increased rat survival and although renal dysfunction already established in CsA treated rats was not reverted by spironolactone, this treatment was able to avoid further renal function deterioration. At structural level, spironolactone produced significant renal protection associated with a reduction of arteriolar thickening, apoptosis and the area affected by tubulo-interstitial fibrosis. The renoprotection conferred by spironolactone in Page 13 of 32 rats with pre-existing chronic CsA nephrotoxicity was associated with reduction of TGFand procaspase-3 mRNA levels.
The role of aldosterone in CsA nephrotoxicity
The potential role of aldosterone as a promoter of vasoconstriction was originally suggested by the observations that primary aldosteronism, a disease due to over secretion of aldosterone, is associated with impaired vascular reactivity (9; 18). In addition, it was reported by Gros et al. (24) indicates that aldosterone induces a down-regulation of endothelial glucose-6-phosphate dehydrogenase that results in impaired oxidative stress and decreased NO availability. Interestingly, these effects of aldosterone were completely prevented by spironolactone (31) . In support to this, we recently shown that spironolactone completely prevented renal acute injury induced by ischemia/reperfusion by a mechanism that involved preservation of renal plasma flow, reestablishment of urinary NO 2 /NO 3 excretion that was accompanied with increased expression of eNOS and phosphorylation at its residue S1177, as well as by a reduction of lipoperoxidation and cell apoptotic death, indicating indeed that aldosterone participates also in hipoperfusion observed in this model (36) . Page 32 of 32
